This biweekly combination is feasible in elderly lung cancer patients with a high burden of comorbidity and dependence. Toxicity is acceptable, whereas response rate and survival fall in the range of active regimens. ADL and IADL indices allow the identification of elderly patients with a worse prognosis.
DA 500 μg q3w showed effectiveness in improving Hb and inducing a clinically significant decrease in CRF of patients with solid tumours undergoing CT. The three instruments, VAS-F, FACT-F and FSI, could be suitable for assessing CRF.
Background: Non-small-cell lung cancer (NSCLC) patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. MAP4 and stathmin have been previously reported as potential markers of resistance to treatment based on microtubule-destabilizing agents. Methods: In this multicenter study, we have used quantitative PCR to analyze the expression of MAP4, stathmin, beta-tubulin III, BRCA1 and ERCC1 using mRNA isolated from peripheral blood samples of 51 non-small-cell lung cancer patients treated with vinorelbine/carboplatin. Results: In a preliminary set, 46 patients with stage IIIB and IV were analyzed. Lower levels of MAP4/OP18 mRNA expression are statistically associated with a response to vinorelbine-based treatment (p=0.029). This significant relationship is maintained in a second analysis after 3rd cycle of treatment (p=0.032). Higher levels of MAP4/op18 were associated with a lower TTP (p=0.05). Conclusions: Our preliminary results suggest that the ratio MAP4/ OP18 may be a good predictor of response for NSCLC patients treated with vinorelbine-based chemotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.